Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720
Maria R. Baer(University of Maryland, Baltimore), Richard A. Larson(Urbana University), Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ben L. Sanford(Duke University), Clara D. Bloomfield(North Shore University Hospital), Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Richard M. Stone(Dana-Farber Cancer Institute), Joseph O. Moore(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Krzysztof Mrózek(The Ohio State University), John Anastasi(Brown University), Stephen L. George(Duke University), Bayard L. Powell(Atrium Health Wake Forest Baptist), Sandra M. Bothun(University of Maryland, Baltimore)
Cited by 131
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k